long intergenic non-protein coding RNA 1877Genealiases: []
Q-omics provides the consensus-scored LINC01877 profile across patient tissues and cancer cell-line models. LINC01877 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, LINC01877 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, LINC01877 RNA expression shows 10,608 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, THCA, and GBM as cancer lineages where LINC01877 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01877 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01877 survival associations across molecular data types. LINC01877 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01877 RNA expression–survival associations across cancer types. High LINC01877 expression shows unfavorable associations in CESC, THCA, DLBC and SKCM, but favorable associations in KIRC and KIRP. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for LINC01877 RNA expression.
This table summarizes LINC01877 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01877. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01877 shows lower tumor expression in THCA, BLCA, BRCA, UCEC, CHOL and LUSC. The THCA box plot shows higher LINC01877 RNA expression in normal versus tumor tissue (log2 FC = −0.267, t-test p < 0.001).
This table shows molecular features associated with LINC01877 in patient tissues and cancer cell lines. In patient samples, LINC01877 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
